Pharmaceutical Technology on MSN21h
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...
GLP-1 Drugs Like Ozempic Reduce Cocaine Cravings, Case Study Finds
A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
FierceBiotech19h
Ascletis' swift surge into obesity continues with competitive oral GLP-1 data
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
FoodBusinessNews20h
Maneuvering in the GLP-1 era
ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...
New Drug in Development to Offset Bone and Muscle Loss From GLP-1 Drugs, but Does It Underscore a Bigger Problem?
Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...
Medscape16h
GLP-1s and Nutrition: A Paradigm Shift Toward Quality and Sustainable Health
GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...
Healthy Returns: Ozempic helps curb alcohol use in new study — and doctors are concerned about telehealth GLP-1s
Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...
GlobalData on MSN15h
Ascletis announces positive results in Phase Ib oral GLP-1RA trial
The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.